奥希替尼治疗EGFR突变NSCLC脑转移患者中 upfront cranial放疗的临床价值
本研究回顾性纳入2家机构205例接受奥希替尼治疗的EGFR突变NSCLC脑转移患者,比较 upfront cranial放疗组与未放疗组的生存结局。结果显示 upfront cranial放疗可显著延长颅内进展时间,在寡脑转移(1-3个病灶且最大径≤3cm)患者中PFS和OS均更优,但多脑转移患者未见差异。
要点
- 寡脑转移患者接受 upfront cranial放疗可改善PFS和OS
- 多脑转移患者 upfront cranial放疗未见生存获益
- 非 upfront 放疗组初始进展中40.2%累及脑,其中76.9%为原部位进展
核心结论
- 在奥希替尼治疗的EGFR突变NSCLC脑转移患者中,寡脑转移状态可作为选择 upfront cranial放疗的潜在因素。
- 需要设计良好的临床试验进一步验证。
研究设计与样本
- 回顾性队列研究,纳入2家机构205例接受奥希替尼标准治疗的NSCLC脑转移患者。
- upfront cranial放疗定义为奥希替尼疾病进展前进行的WBRT或/和SRS,排除既往EGFR-TKI治疗期间进行的放疗。
- 采用倾向性评分匹配(PSM)分析校正协变量。
- 寡脑转移定义为1-3个脑转移灶且最大径≤3cm,否则为多脑转移。
主要发现
- 205例中奥希替尼一线治疗74例,二线治疗131例。
- 48例接受 upfront cranial放疗,其中WBRT 24例,SRS 24例。
- upfront cranial放疗组中寡脑转移患者全部接受SRS(n=17),多脑转移患者中90.3%(n=28)接受WBRT。
- 非 upfront 放疗组初始进展中40.2%累及脑,脑进展中76.9%为原部位进展。
关键数值与推荐
- 寡脑转移定义:1-3个脑转移灶,最大径≤3cm。
临床怎么用
- 对于奥希替尼治疗的EGFR突变NSCLC脑转移患者,可考虑根据寡脑转移状态选择 upfront cranial放疗。
- 寡脑转移患者可能从 upfront cranial放疗(尤其SRS)中获益。
- 多脑转移患者 upfront cranial放疗的获益尚不明确。
局限性
- 回顾性研究设计。
- 样本量有限(205例)。
- 需要前瞻性临床试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib has a powerful ability to penetrate the blood-brain barrier and a high potency for controlling brain metastases (BMs) from EGFR-mutant non-small cell lung cancer (NSCLC). The clinical value of cranial radiation therapy in osimertinib-treated NSCLC with BMs remains largely unknown. METHODS AND MATERIALS: Patients with NSCLC and BMs and receiving osimertinib treatment as the standard of care were retrospectively enrolled from 2 institutions. Cranial radiation therapy (RT; whole-brain radiation therapy [WBRT] or/and stereotactic radiosurgery [SRS]) performed before disease progression (PD) to osimertinib was categorized as upfront cranial radiation therapy (ucRT group), excluding those treatments performed during prior EGFR-TKI treatment. Overall survival (OS), progression-free survival (PFS), and the time to intracranial progression (iTTP) were compared between the 2 groups, with adjustment by covariates in propensity-score matched (PSM) analyses. The state of having 1 to 3 BM lesions, with a maximal size of ≤3 cm, was defined as having oligo-BM; otherwise; the cases were defined as having multiple BMs. RESULTS: Of the 205 patients enrolled, osimertinib was used as first-line therapy in 74 and second-line therapy in 131. There were 48 patients who received ucRTs, including WBRT in 24 and SRS in 24. All patients with oligo-BM in the ucRT group received SRS alone (n = 17), whereas most (n = 28; 90.3%) patients with multiple BMs received WBRT. Failure pattern analyses indicated that in the non-ucRT group, 40.2% of the initial PD involved the brain and 76.9% of the cranial PD involved the original sites, indicating the potential roles of ucRT. Indeed, the iTTP was significantly prolonged (P = .010) in the ucRT group among the whole population. In the PSM oligo-BM cohort, the ucRT group showed superior PFS (P = .033) and OS (P = .026) compared with the non-ucRT group, and the differences remained after multivariate Cox analyses. No such differences were observed in the subpopulation with multiple BMs. CONCLUSIONS: In osimertinib-treated NSCLC patients with BMs, oligo-BM status could be used as a potential factor to select patients for upfront cranial RT. Further investigation by well-designed clinical trials is warranted.
引用
- Yu F, Ni J, Zeng W, et al. Clinical Value of Upfront Cranial Radiation Therapy in Osimertinib-Treated Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer With Brain Metastases. Int J Radiat Oncol Biol Phys. 2021. PMID: 34058255. doi:10.1016/j.ijrobp.2021.05.125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。